The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study

Szabina Szujo, Livia Sira, L. Bajnok, Beata Bodis, Ferenc Gyory, Orsolya Nemes, Karoly Rucz, Peter Kenyeres, Zsuzsanna Valkusz, Krisztian Sepp, Erzsebet Schmidt, Zsuszanna Szabo, Sarolta Szekeres, Katalin Zambo, Sandor Barna, E. Nagy, E. Mezősi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of post-radioiodine therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis. Patients and methods: 323 consecutive patients were investigated after their first radioiodine treatment (1100-3700 MBq). Both whole body scan and SPECT/CT images of the head, neck, chest and abdomen regions were taken 4-6 days after radioiodine therapy. Patients were re-evaluated 9-12 months later as well as at the end of follow up (median 37 months). Results: Post-radioiodine therapy SPECT/CT showed metastases in 22% of patients. Lymph node, lung and bone metastases were detected in 61, 13 and 5 patients, respectively, resulting in early reclassification of 115 cases (36%). No evidence of disease was found in 251 cases at 9-12 months after radioiodine treatment and 269 patients at the end of follow-up. To predict residual disease at the end of follow-up, the sensitivities, specificities and diagnostic accuracies of the current risk classification systems and SPECT/CT were: ATA: 77%, 47% and 53%; ETA: 70%, 62% and 64%; SPECT/CT: 61%, 88% and 83%, respectively. There was no difference between cohorts of the two institutions when data were analyzed separately. Conclusions: Based on our bi-institutional experience, the accuracy of postradioiodine SPECT/CT outweighs that of the currently used ATA and ETA risk classification systems in the prediction of long-term outcome of DTC.

Original languageEnglish
Pages (from-to)79825-79834
Number of pages10
JournalOncotarget
Volume8
Issue number45
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Thyroid Neoplasms
Therapeutics
Neoplasm Metastasis
Whole Body Imaging
Single Photon Emission Computed Tomography Computed Tomography
Single-Photon Emission-Computed Tomography
Abdomen
Neck
Thorax
Lymph Nodes
Head
Bone and Bones
Sensitivity and Specificity
Lung

Keywords

  • ATA risk classification
  • Differentiated thyroid cancer
  • ETA risk classification
  • Radioiodine therapy
  • SPECT/CT

ASJC Scopus subject areas

  • Oncology

Cite this

The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study. / Szujo, Szabina; Sira, Livia; Bajnok, L.; Bodis, Beata; Gyory, Ferenc; Nemes, Orsolya; Rucz, Karoly; Kenyeres, Peter; Valkusz, Zsuzsanna; Sepp, Krisztian; Schmidt, Erzsebet; Szabo, Zsuszanna; Szekeres, Sarolta; Zambo, Katalin; Barna, Sandor; Nagy, E.; Mezősi, E.

In: Oncotarget, Vol. 8, No. 45, 01.01.2017, p. 79825-79834.

Research output: Contribution to journalArticle

Szujo, S, Sira, L, Bajnok, L, Bodis, B, Gyory, F, Nemes, O, Rucz, K, Kenyeres, P, Valkusz, Z, Sepp, K, Schmidt, E, Szabo, Z, Szekeres, S, Zambo, K, Barna, S, Nagy, E & Mezősi, E 2017, 'The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study', Oncotarget, vol. 8, no. 45, pp. 79825-79834. https://doi.org/10.18632/oncotarget.19781
Szujo, Szabina ; Sira, Livia ; Bajnok, L. ; Bodis, Beata ; Gyory, Ferenc ; Nemes, Orsolya ; Rucz, Karoly ; Kenyeres, Peter ; Valkusz, Zsuzsanna ; Sepp, Krisztian ; Schmidt, Erzsebet ; Szabo, Zsuszanna ; Szekeres, Sarolta ; Zambo, Katalin ; Barna, Sandor ; Nagy, E. ; Mezősi, E. / The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study. In: Oncotarget. 2017 ; Vol. 8, No. 45. pp. 79825-79834.
@article{a682e38051244294b3b80f0f47dab087,
title = "The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study",
abstract = "Objective: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of post-radioiodine therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis. Patients and methods: 323 consecutive patients were investigated after their first radioiodine treatment (1100-3700 MBq). Both whole body scan and SPECT/CT images of the head, neck, chest and abdomen regions were taken 4-6 days after radioiodine therapy. Patients were re-evaluated 9-12 months later as well as at the end of follow up (median 37 months). Results: Post-radioiodine therapy SPECT/CT showed metastases in 22{\%} of patients. Lymph node, lung and bone metastases were detected in 61, 13 and 5 patients, respectively, resulting in early reclassification of 115 cases (36{\%}). No evidence of disease was found in 251 cases at 9-12 months after radioiodine treatment and 269 patients at the end of follow-up. To predict residual disease at the end of follow-up, the sensitivities, specificities and diagnostic accuracies of the current risk classification systems and SPECT/CT were: ATA: 77{\%}, 47{\%} and 53{\%}; ETA: 70{\%}, 62{\%} and 64{\%}; SPECT/CT: 61{\%}, 88{\%} and 83{\%}, respectively. There was no difference between cohorts of the two institutions when data were analyzed separately. Conclusions: Based on our bi-institutional experience, the accuracy of postradioiodine SPECT/CT outweighs that of the currently used ATA and ETA risk classification systems in the prediction of long-term outcome of DTC.",
keywords = "ATA risk classification, Differentiated thyroid cancer, ETA risk classification, Radioiodine therapy, SPECT/CT",
author = "Szabina Szujo and Livia Sira and L. Bajnok and Beata Bodis and Ferenc Gyory and Orsolya Nemes and Karoly Rucz and Peter Kenyeres and Zsuzsanna Valkusz and Krisztian Sepp and Erzsebet Schmidt and Zsuszanna Szabo and Sarolta Szekeres and Katalin Zambo and Sandor Barna and E. Nagy and E. Mezősi",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19781",
language = "English",
volume = "8",
pages = "79825--79834",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "45",

}

TY - JOUR

T1 - The impact of post-radioiodine therapy SPECT/CT on early risk stratification in differentiated thyroid cancer; a bi-institutional study

AU - Szujo, Szabina

AU - Sira, Livia

AU - Bajnok, L.

AU - Bodis, Beata

AU - Gyory, Ferenc

AU - Nemes, Orsolya

AU - Rucz, Karoly

AU - Kenyeres, Peter

AU - Valkusz, Zsuzsanna

AU - Sepp, Krisztian

AU - Schmidt, Erzsebet

AU - Szabo, Zsuszanna

AU - Szekeres, Sarolta

AU - Zambo, Katalin

AU - Barna, Sandor

AU - Nagy, E.

AU - Mezősi, E.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of post-radioiodine therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis. Patients and methods: 323 consecutive patients were investigated after their first radioiodine treatment (1100-3700 MBq). Both whole body scan and SPECT/CT images of the head, neck, chest and abdomen regions were taken 4-6 days after radioiodine therapy. Patients were re-evaluated 9-12 months later as well as at the end of follow up (median 37 months). Results: Post-radioiodine therapy SPECT/CT showed metastases in 22% of patients. Lymph node, lung and bone metastases were detected in 61, 13 and 5 patients, respectively, resulting in early reclassification of 115 cases (36%). No evidence of disease was found in 251 cases at 9-12 months after radioiodine treatment and 269 patients at the end of follow-up. To predict residual disease at the end of follow-up, the sensitivities, specificities and diagnostic accuracies of the current risk classification systems and SPECT/CT were: ATA: 77%, 47% and 53%; ETA: 70%, 62% and 64%; SPECT/CT: 61%, 88% and 83%, respectively. There was no difference between cohorts of the two institutions when data were analyzed separately. Conclusions: Based on our bi-institutional experience, the accuracy of postradioiodine SPECT/CT outweighs that of the currently used ATA and ETA risk classification systems in the prediction of long-term outcome of DTC.

AB - Objective: SPECT/CT has numerous advantages over planar and traditional SPECT images. The aim of this study was to evaluate the role of post-radioiodine therapy SPECT/CT of patients with differentiated thyroid cancer (DTC) in early risk classification and in prediction of late prognosis. Patients and methods: 323 consecutive patients were investigated after their first radioiodine treatment (1100-3700 MBq). Both whole body scan and SPECT/CT images of the head, neck, chest and abdomen regions were taken 4-6 days after radioiodine therapy. Patients were re-evaluated 9-12 months later as well as at the end of follow up (median 37 months). Results: Post-radioiodine therapy SPECT/CT showed metastases in 22% of patients. Lymph node, lung and bone metastases were detected in 61, 13 and 5 patients, respectively, resulting in early reclassification of 115 cases (36%). No evidence of disease was found in 251 cases at 9-12 months after radioiodine treatment and 269 patients at the end of follow-up. To predict residual disease at the end of follow-up, the sensitivities, specificities and diagnostic accuracies of the current risk classification systems and SPECT/CT were: ATA: 77%, 47% and 53%; ETA: 70%, 62% and 64%; SPECT/CT: 61%, 88% and 83%, respectively. There was no difference between cohorts of the two institutions when data were analyzed separately. Conclusions: Based on our bi-institutional experience, the accuracy of postradioiodine SPECT/CT outweighs that of the currently used ATA and ETA risk classification systems in the prediction of long-term outcome of DTC.

KW - ATA risk classification

KW - Differentiated thyroid cancer

KW - ETA risk classification

KW - Radioiodine therapy

KW - SPECT/CT

UR - http://www.scopus.com/inward/record.url?scp=85030478941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030478941&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19781

DO - 10.18632/oncotarget.19781

M3 - Article

AN - SCOPUS:85030478941

VL - 8

SP - 79825

EP - 79834

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -